HealthCare Royalty in deals with Agenus, Albireo
Agenus Inc. (NASDAQ:AGEN) said it will sell to HealthCare Royalty Partners (Stamford, Conn.) royalty rights on sales of vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) containing Agenus' QS-21 Stimulon adjuvant. The biotech will receive $190 million in cash, plus up to $40 million in milestones.
Agenus gained $0.40 (11%) to $3.91 Monday...